Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21

Science

Volumn 328, Issue 5979, 2010, Pages 749-752

  Shields, Jacqueline D ^a   Kourtis, Iraklis C ^a   Tomei, Alice A ^a   Roberts, Joanna M ^a   Swartz, Melody A ^a  

^a EPFL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; SECONDARY LYMPHOID TISSUE CHEMOKINE;

CANCER; HOST; IMMUNE RESPONSE; IMMUNE SYSTEM; RODENT; TUMOR;

ANIMAL CELL; ANTIGEN PRESENTING CELL; ARTICLE; CANCER SURVIVAL; CARCINOGENESIS; CELL POPULATION; CONTROLLED STUDY; DISEASE ASSOCIATION; GRAFT REJECTION; HOST; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; LYMPHOID CELL; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STROMA; TUMOR ESCAPE; TUMOR GROWTH;

ANIMALS; ANTIGEN-PRESENTING CELLS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CHEMOKINE CCL21; CYTOKINES; DISEASE PROGRESSION; FEMALE; IMMUNE TOLERANCE; LYMPH NODES; LYMPHOID TISSUE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; RECEPTORS, CCR7; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STROMAL CELLS; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY; TUMOR ESCAPE;

MUS;

EID: 77952231121     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1185837     Document Type: Article

References (30)

1. A. Ben-Baruch, Cancer Metastasis Rev. 25, 357 (2006).
2. A. Mantovani, P. Allavena, A. Sica, F. Balkwill, Nature 454, 436 (2008).
3. W. Zou, Nat Rev. Cancer 5, 263 (2005).
4. M. A. Schneider, J. G. Meingassner, M. Lipp, H. D. Moore, A. Rot, 7. Exp. Med. 204, 735 (2007).
5. A. Menning et al., Eur. J. Immunol. 37, 1575 (2007).
6. J.. C. Ochando et al., J. Immunol 174, 6993 (2005).
7. R. Förster, A. C. Davalos-Misslitz, A. Rot, Nat. Rev. Immunol. 8, 362 (2008).
8. A. C. Davalos-Misslitz et a.l., Eur. J. Immunol. 37, 613 (2007).
9. J. W. Lee et al., Nat Immunol. 8, 181 (2007).
10. S. N. Mueller, R. N. Germain, Nat. Rev. Immunol. 9, 618 (2009).
11. A. Link et al., Nat. Immunol. 8, 1255 (2007).
12. J. D. Shields et al., Cancer Cell 11, 526 (2007).
13. T. D. Randall, D. M. Carragher, J. Rangel-Moreno, Annu. Rev. Immunol. 26, 627 (2008).
14. D. L. Drayton, S. Liao, R. H. Mounzer, N. H. Ruddle, Nat. Immunol. 7, 344 (2006).
15. W. Weninger et al., J. Immunol. 170, 4638 (2003).
16. G. Eberl, D. R. Liftman, Immunol. Rev. 195, 81 (2003).
17. L. Peduto et al., J. Immunol. 182, 5789 (2009).
18. S. Krautwald et al., Immunology 112, 301 (2004).
19. E. Ziegler et al., J. Am. Soc. Nephrol. 17, 2521 (2006).
20. Materials and methods are available as supporting material on Science Online.
21. B. Biene, H. L. Moses, Nat. Rev. Cancer 6, 506 (2006).
22. A. Sica et al., Semin. Cancer Biol. 18, 349 (2008).
23. G. Eberl et al., Nat. Immunol. 5, 64 (2004).
24. A. Kawase et al., Int. J. Cancer 123, 1053 (2008).
25. G. C. Prendergast, Oncogene 27, 3889 (2008).
26. J. C. Varela et al., Cancer Res. 68, 6734 (2008).
27. J. A. Joyce et al., Cancer Cell 4, 393 (2003).
28. M. R. Britschgi, A. Link, T. K. Lissandrin, S. A. Luther, J. Immunol. 181, 7681 (2008).
29. Single-letter abbreviations for the amino acid residues are as follows: A, Ala; C, Cys; D, Asp; E, GIu; F, Phe; G, Gly; H, His; I, lle; K, Lys; L, Leu; M, Met; N, Asn; P, Pro; Q, Gln; R, Arg; S, Ser; T, Thr; V, Val; W, Trp; and Y, Tyr.
30. -/- mice, D. Hanahan for β tumor cells, and D. Trono for lentiviral vector Plasmids; S. Pradervand, A. Paillusson, D. Foretay, M. Pasquier, V. Borel, B. Dixon, and A. Jimenez for technical assistance; and J. Hubbell and G. Eberl for critical reading of the manuscript. Funding was provided by the Swiss Cancer League, the Swiss National Science Foundation, the European Research Council, and the U.S. Department of Defense Breast Cancer Research Program to M.A.S. The authors (except J.M.R.) have filed a patent application on the use of CCL21 in immune modulation.